The global idiopathic thrombocytopenic purpura therapeutics market is expected to grow at a CAGR of 5.4% during the period 2022 to 2032. The market is valued at US$ 642 million as of 2022, and by 2032, the market is expected to be valued at US$ 1,086.28 million.
| Attributes | Value |
|---|---|
| Idiopathic Thrombocytopenic Purpura Therapeutics Market Value (2022) | US$ 642 million |
| Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast Value (2032) | US$ 1086.28 million |
| Idiopathic Thrombocytopenic Purpura Therapeutics Market Expected CAGR (2022 to 2032) | 5.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In the recent times, there has been a rising clamor for combination therapies, which is expected to surge the demand for idiopathic thrombocytopenic purpura therapeutics. The clinical studies suggest that the combination therapies entail lower side effects and display higher response rates. Apart from that, these are cost effective as well, which makes them one of the most sought-after methods.
Furthermore, an increase in the number of blood related disorders is also expected to boost the market growth of ITP test during the forecast period. Apart from that the implementation of latest technologies in the healthcare sector, coupled with innovative practices is also expected to surge the demand. Moreover, the key players serving the niche are investing massive amounts in R&D, which is expected to have a positive influence on the idiopathic thrombocytopenic purpura therapeutics adoption trends.
This method generally makes use of corticosteroids which are responsible for maintaining normal platelet count. The corticosteroids are easily available in the market, as result of which there are no scope of resource shortage involved in this method. This is expected to have a strong effect on the idiopathic thrombocytopenic purpura therapeutics market outlook.
Furthermore, an increased availability of number of drugs pertaining to ITP therapeutics in retail pharmacies presents massive prospects for the market growth. Apart from that, the availability of such drugs through E-commerce platform has made life easier for a lot of patients.
One of the biggest restraints involved is the side effects on the health conditions. Some of the ITP symptoms in adults are bleeding disorders, infection, blood clots, etc. Additionally, excessive use of corticosteroids leads to vomiting, nausea, etc. Furthermore, the high cost associated with this process is also expected to hamper market growth.
By product
Based on the product, the TPO-RA segment has the highest market share. High response rates exhibited by the patients when administered with TPA-RA is expected to be the main reason behind the segment gaining a lot of traction.
However, the fastest growing segment is expected to be corticosteroids. The low price of corticosteroids makes it the fastest growing segment.
By region
Based on the regional analysis, North America is expected to be the largest market during the forecast period. An increasing demand for combination therapy in the region, coupled with the advancement in the healthcare facilities makes North America the largest market.
However, Asia-Pacific is expected to be the fastest growing market during the forecast period. Increasing investments by the government in the healthcare sector, coupled with the influx of major players serving the niche is expected to surge the market share.
Idiopathic thrombocytopenic purpura is an autoimmune disorder clinically diagnosed as acquired bleeding disorder in which platelets (blood cells) are destroyed by immune system, who play an important role in primary and secondary haemostasis. Idiopathic thrombocytopenic purpura is characterised by tendency to bleed continuously mostly from extremities such as nose and gums, purpuric rash and petechiae.
Individuals with idiopathic thrombocytopenic purpura have platelet count below normal (less than 150,000 cells/mm3) causing thrombocytopenia. Idiopathic thrombocytopenic purpura can be acute for chronic with platelet count less than 150,000 cells/mm3 and 50,000 cells/mm3 respectively.
In fatal or sever idiopathic thrombocytopenic purpura intracerebral or subarachnoid hemorrhage, lower gastrointestinal bleeding or other internal bleeding may occur.In idiopathic thrombocytopenic purpura activation of lymphocytes leads to anti-platelet antibodies against the fibrinogen receptor i.e platelet glycoproteins IIb/IIIa.
Incidence of idiopathic thrombocytopenic purpura in children and adult population is approximately 50 and 66 cases per 1,000,000 per year respectively.
Commonly utilised tests for diagnosis of idiopathic thrombocytopenic purpura include blood typing, blood count, direct Coombs testing, evaluation of peripheral smear, bone marrow evaluation, immunoglobulin quantitation and evaluation for platelet antibodies.
More advanced tests may be performed such as platelet binding assay, genetic mutational analysis and bone marrow cultures for megakaryocyte growth and differentiation. Testing of H. pylori infection is considered as a standard diagnostic test for individuals suspected of idiopathic thrombocytopenic purpura, in countries with higher incidence of H. pylori infection.
Treatment for idiopathic thrombocytopenic purpura mainly aims for normal platelet count to prevent excessive bleeding. First line therapy generally used in of idiopathic thrombocytopenic purpura is oral corticosteroids, such as prednisone, rituximab, azathioprine, eltrombopag, methylprednisolone etc.
Second line treatment generally used is spleenectomy while new treatment measures include intravenous immunoglobulin (IVIG), anti-D immunoglobulin and thrombopoietin receptor agonists (TPO-RA).
Principal Consultant
In most cases of idiopathic thrombocytopenic purpura treatment generally involves use of corticosteroids that maintain normal platelet count. Easy availability and accessibility of corticosteroid has been one of the major factor in driving idiopathic thrombocytopenic purpura therapeutics market.
New advances in proper diagnosis, government initiatives in awareness and treatment of disease and association of idiopathic thrombocytopenic purpura with pregnancy, infections or immunosuppressive diseases (H. pylori) has been a reason for market growth of idiopathic thrombocytopenic purpura therapeutics market.
The most important drivers for idiopathic thrombocytopenic purpura therapeutics market is use of effective combination therapy, introduction of new drugs such as intravenous immunoglobulin (IVIG) and thrombopoietin receptor agonists (TPO-RA) in treatment of idiopathic thrombocytopenic purpura therapeutics market.
There have been published report where use of dexamethasone alone and alongwith infusions of rituximab was tested. It was found that dexamethasone with rituximab had rendered safe platelet count for about 6 months in 63% of individuals in study. Also another published study stated that use of TPO mimetic drugs sustained normal platelet count in 85% of indivivduals thus boosting market for for idiopathic thrombocytopenic purpura therapeutics.
Major restraint for for idiopathic thrombocytopenic purpura therapeutics market is side effects of corticosteroids or drugs used. But use of combination therapy and new drugs has seen to avoid side effects and proved life saving.
Another restraint for idiopathic thrombocytopenic purpura therapeutics market is lack of awareness of disease amongst people, no facilities for diagnostic test in rural areas and high cost of treatment in low income countries. Non-adherence of patients to combination treatment has also been a major part in restraining for idiopathic thrombocytopenic purpura therapeutics market.
The global idiopathic thrombocytopenic purpura therapeutics market is governed by drugs that suppress uimmune system, injections that increase blood count and drugs that boost platelet production. Association of idiopathic thrombocytopenic purpura with other infections such as H. pylori infection and others related to immunosuppression favours market for idiopathic thrombocytopenic purpura therapeutics.
Inspite of low global incidence of idiopathic thrombocytopenic purpura, its fatal and serious complications has led advancement in its treatment leading to rise in idiopathic thrombocytopenic purpura therapeutics market. Use of efficient combination therapy has driven idiopathic thrombocytopenic purpura therapeutics market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Region wise, the idiopathic thrombocytopenic purpura therapeutics market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.
North America is the largest market for idiopathic thrombocytopenic purpura therapeutics due to demand for combination therapy, advancement in healthcare facilities and mainly due to Orphan drug act in U.S. Owing to drugs such as romiplostim have driven Idiopathic thrombocytopenic purpura market in Japan and Europe too. India is seen to have stable rise in idiopathic thrombocytopenic purpura therapeutics market.
Some of the key players in idiopathic thrombocytopenic purpura market include GlaxoSmithKline, Amgen. Inc, Grifols S.A, CSL Behring, Baxter, Sandoz, Contract Pharmacal, Roxane and others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global idiopathic thrombocytopenic purpura therapeutics market is classified on the basis of treatment, distribution channel and geography.
Based on treatment, the global idiopathic thrombocytopenic purpura therapeutics market is segmented into the following:
Based on distribution channels, the global idiopathic thrombocytopenic purpura therapeutics market is segmented into the following:
The market is likely to register a CAGR of 5.4% through 2032.
What is the Current Valuation of the Market? The market is currently valued at US$ 642 Mn in 2022.
The market is likely to grow to a valuation of US$ 1086.28 Mn by 2032.
North America is likely to be a leading market during the forecast period.
Explore Healthcare Insights
View Reports
Idiopathic Thrombocytopenic Purpura Therapeutics Market
